Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada — Clinical Trial Site

58 Registered trials

21 Currently recruiting

Organisation

Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada

Location

Manresa, Spain

Identifier

ORG-100045540

Address

Dr Joan Soler 1-3, 08243, Spain

Departments

7004: Medical Oncology
Allergology
Anaesthesiology
cirugia
Departamento de oncologia
Gastroenterología
Haematology and Haemotherapy
Hematología
Hematology
Medica Oncology
Medical Oncology
Medicina interna
N/A
Neumology
Oncología
Oncology
Oncology department
Oncology Service
Ophtalmology
PSIQUIATRIA
Rheumatology
Servicio de Medicina Interna
Servicio de Oncología Médica
Servicio Oncologia Medica

Clinical trials at this site (58)

Search interface

“USE OF A FIBRIN ADHESIVE TO REDUCE ESOPHAGOYEJUNAL ANASTOMOSIS DEHISCENCE IN TOTAL GASTRECTOMIES FOR CANCER: RANDOMIZED AND MULTICENTER STU… Pending

2024-519529-40-00 ESOPHAGOYEJUNAL ANASTOMOSIS DEHISCENCE IN TOTAL GASTREC 5
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5
A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf… Pending

2025-521230-29-00 Allergic rhinoconjunctivitis to Dermatophagoides pteron 5
Prospective, randomized, multicentre study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the pr… Pending

2025-521301-40-00 Prevention of new morphometric vertebral fractures and/ 6
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0… Pending

2025-523058-16-00 Skin Toxicities Associated with Epidermal Growth Factor 4
Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending

2025-523793-16-00 Homeostatic iron regulator gene-related hereditary hemo 4
A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s… Pending

2025-524843-11-00 Non-Small Cell Lung Cancer 4
SIE-1 Recruiting

2025-523269-31-00 Hormone receptor-positive early breast cancer in post-m 3 2026-06-02
A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors Recruiting

2025-523742-27-00 Advanced solid tumors 9 2026-04-28
A study for adolescents who are depressed and thinking of suicide Recruiting

2024-518615-19-00 Major Depressive Disorder 5 2026-04-22
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced … Recruiting

2023-503221-19-00 Advanced Non-Small Cell Lung Cancer 4 2024-04-18
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re… Recruiting

2024-515201-26-00 Small cell lung cancer (SCLC) 4 2025-12-09
Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, ra… Recruiting

2024-513465-39-00 Acute bacterial prostatitis 6 2024-12-04
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting

2022-502408-57-00 Novo metastatic hormone-sensitive prostate cancer (mHSP 5 2024-09-04
N-PLUS Recruiting

2022-502559-69-01 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 201 4 2024-07-04
Efficacy of perioperative duloxetine in patients at high risk for developing chronic postsurgical pain after inguinal hernia repair: a multi… Recruiting

2023-505860-12-00 Chronic postsurgical pain after inguinal hernia repair 5 2024-06-26
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19